<DOC>
	<DOC>NCT01926769</DOC>
	<brief_summary>To determine the safety and efficacy of second-line treatment with Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the second line treatment of advanced colorectal cancer</brief_summary>
	<brief_title>A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>age over 18 histologically confirmted advanced colorectal cancer ECOG PS 02 expected life span more than 3months normal bone marrow, liver, renal function 5FU, oxaliplatin, irinotecan or Metformin Allergic history Lactic acidosis, metabolic acidosis active infection or severe neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Metformin</keyword>
	<keyword>FOLFOX6</keyword>
	<keyword>FOFIRI</keyword>
	<keyword>5FU</keyword>
	<keyword>irinotecan</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>